HMG-CoA reductase inhibitors enhance phagocytosis by upregulating ATP-binding cassette transporter A7

Atherosclerosis

Volumn 217, Issue 2, 2011, Pages 407-414

  Tanaka, Nobukiyo ^a,b   Abe Dohmae, Sumiko ^a   Iwamoto, Noriyuki ^a,d   Fitzgerald, Michael L ^c   Yokoyama, Shinji ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b Ichinomiyanishi Hospital   (Japan)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

ABCA7; Atherosclerosis; Cholesterol; HMG CoA reductase inhibitor; Phagocytosis; Statin

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER A1; ABC TRANSPORTER A7; CHOLESTEROL; CYCLODEXTRIN; MESSENGER RNA; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; SMALL INTERFERING RNA; STEROL REGULATORY ELEMENT BINDING PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CHOLESTEROL; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; JURKAT CELLS; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHAGOCYTOSIS; PRAVASTATIN; PYRIMIDINES; RNA INTERFERENCE; RNA, MESSENGER; SIMVASTATIN; SULFONAMIDES; TRANSFECTION; UP-REGULATION;

EID: 79960700354     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.06.031     Document Type: Article

References (45)

1. Goldstein J.L., Brown M.S. The LDL receptor. Arterioscler Thromb Vasc Biol 2009, 29:431-438.
2. 4S Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
3. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301-1307.
4. Sacks F.M., Moye L.A., Davis B.R., et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation 1998, 97:1446-1452.
5. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001, 285:1711-1718.
6. Simes R.J., Marschner I.C., Hunt D., et al. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?. Circulation 2002, 105:1162-1169.
7. Collins MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
8. Rosenson R.S., Tangney C.C., Casey L.C. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999, 353:983-984.
9. Pahan K., Sheikh F.G., Namboodiri A.M., Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 1997, 100:2671-2679.
10. Konstantinopoulos P.A., Karamouzis M.V., Papavassiliou A.G. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov 2007, 6:541-555.
11. Morimoto K., Janssen W.J., Fessler M.B., et al. Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease. J Immunol 2006, 176:7657-7665.
12. Wu Y.C., Horvitz H.R. The C. elegans cell corpse engulfment gene ced-7 encodes a protein similar to ABC transporters. Cell 1998, 93:951-960.
13. Williamson P., Schlegel R.A. Transbilayer phospholipid movement and the clearance of apoptotic cells. Biochim Biophys Acta 2002, 1585:53-63.
14. Hamon Y., Broccardo C., Chambenoit O., et al. ABC1 promotes engulfment of apoptotic cells and transbilayer redistribution of phosphatidylserine. Nat Cell Biol 2000, 2:399-406.
15. Bared S.M., Buechler C., Boettcher A., et al. Association of ABCA1 with syntaxin 13 and flotillin-1 and enhanced phagocytosis in tangier cells. Mol Biol Cell 2004, 15:5399-5407.
16. Iwamoto N., Abe-Dohmae S., Sato R., Yokoyama S. ABCA7 expression is regulated by cellular cholesterol through the SREBP2 pathway and associated with phagocytosis. J Lipid Res 2006, 47:1915-1927.
17. Jehle A.W., Gardai S.J., Li S., et al. ATP-binding cassette transporter A7 enhances phagocytosis of apoptotic cells and associated ERK signaling in macrophages. J Cell Biol 2006, 174:547-556.
18. Kaminski W.E., Orso E., Diederich W., Klucken J., Drobnik W., Schmitz G. Identification of a novel human sterol-sensitive ATP-binding cassette transporter (ABCA7). Biochem Biophys Res Commun 2000, 273:532-538.
19. Bodzioch M., Orso E., Klucken J., et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 1999, 22:347-351.
20. Brooks-Wilson A., Marcil M., Clee S.M., et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 1999, 22:336-345.
21. Rust S., Rosier M., Funke H., et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 1999, 22:352-355.
22. Kim W.S., Fitzgerald M.L., Kang K., et al. Abca7 null mice retain normal macrophage phosphatidylcholine and cholesterol efflux activity despite alterations in adipose mass and serum cholesterol levels. J Biol Chem 2005, 280:3989-3995.
23. Linsel-Nitschke P., Jehle A.W., Shan J., et al. Potential role of ABCA7 in cellular lipid efflux to apoA-I. J Lipid Res 2005, 46:86-92.
24. Venkateswaran A., Laffitte B.A., Joseph S.B., et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc Natl Acad Sci U S A 2000, 97:12097-12102.
25. Costet P., Luo Y., Wang N., Tall A.R. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem 2000, 275:28240-28245.
26. Repa J.J., Turley S.D., Lobaccaro J.A., et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 2000, 289:1524-1529.
27. Tanaka N., Abe-Dohmae S., Iwamoto N., Fitzgerald M.L., Yokoyama S. Helical apolipoproteins of high-density lipoprotein enhance phagocytosis by stabilizing ATP-binding cassette transporter A7. J Lipid Res 2010, 51:2591-2599.
28. Sadeghi M.M., Collinge M., Pardi R., Bender J.R. Simvastatin modulates cytokine-mediated endothelial cell adhesion molecule induction: involvement of an inhibitory G protein. J Immunol 2000, 165:2712-2718.
29. Hu W., Abe-Dohmae S., Tsujita M., et al. Biogenesis of HDL by SAA is dependent on ABCA1 in the liver in vivo. J Lipid Res 2008, 49:386-393.
30. Yokoyama S., Tajima S., Yamamoto A. The process of dissolving apolipoprotein A-I in an aqueous buffer. J Biochem 1982, 91:1267-1272.
31. Abe-Dohmae S., Suzuki S., Wada Y., Aburatani H., Vance D.E., Yokoyama S. Characterization of apolipoprotein-mediated HDL generation induced by cAMP in a murine macrophage cell line. Biochemistry 2000, 39:11092-11099.
32. Kiss R.S., Elliott M.R., Ma Z., Marcel Y.L., Ravichandran K.S. Apoptotic cells induce a phosphatidylserine-dependent homeostatic response from phagocytes. Curr Biol 2006, 16:2252-2258.
33. Tanaka N., Abe-Dohmae1 S., Iwamoto N., Fitzgerald M.L., Yokoyama S. Helical apolipoproteins of high-density lipoprotein enhance phagocytosis by stabilizing ATP-binding cassette transporter A7. J Lipid Res 2010, 51:2591-2599.
34. The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.
35. The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering, JAMA 1984;251:365-74.
36. Pedersen T.R. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
37. Pedersen T.R., Olsson A.G., Faergeman O., et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998, 97:1453-1460.
38. Bisoendial R.J., Stroes E.S., Kastelein J.J., Tak P.P. Targeting cardiovascular risk in rheumatoid arthritis: a dual role for statins. Nat Rev Rheumatol 2010, 6:157-164.
39. Rueckschloss U., Galle J., Holtz J., Zerkowski H.R., Morawietz H. Induction of NAD(P)H oxidase by oxidized low-density lipoprotein in human endothelial cells: antioxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy. Circulation 2001, 104:1767-1772.
40. Mason R.P., Walter M.F., Jacob R.F. Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress. Circulation 2004, 109:II34-II41.
41. Bocan T.M. Pleiotropic effects of HMG-CoA reductase inhibitors. Curr Opin Investig Drugs 2002, 3:1312-1317.
42. Schrijvers D.M., De Meyer G.R., Kockx M.M., Herman A.G., Martinet W. Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis. Arterioscler Thromb Vasc Biol 2005, 25:1256-1261.
43. Salman H., Bergman M., Djaldetti M., Bessler H. Hydrophobic but not hydrophilic statins enhance phagocytosis and decrease apoptosis of human peripheral blood cells in vitro. Biomed Pharmacother 2008, 62:41-45.
44. Rabini R.A., Polenta M., Staffolani R., et al. Effect of hydroxymethylglutaryl-CoA reductase inhibitors on the functional properties of erythrocyte membranes. Exp Mol Pathol 1993, 59:51-57.
45. Koter M., Broncel M., Chojnowska-Jezierska J., Klikczynska K., Franiak I. The effect of atorvastatin on erythrocyte membranes and serum lipids in patients with type-2 hypercholesterolemia. Eur J Clin Pharmacol 2002, 58:501-506.